Overview

Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking adefovir dipivoxil.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Collaborator:
Novartis Pharmaceuticals
Treatments:
Adefovir
Adefovir dipivoxil
Telbivudine